Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’ Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, emerging HER2-targeting drugs currently in development are forecasted to enter the market, while current HER2-targeting agents see their sales changing as a result of competition, label expansions, biosimilars entry and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Telzenna) and PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq) and anticipated future entry of agents within these drug classes will provide more diverse treatment options, especially for triple-negative breast cancer.

Questions answered

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as the CDK4/6 inhibitors, immune checkpoint inhibitors, and PARP inhibitors in the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Contents Highlights

Geographies: United States, EU5, Japan

Primary Research: 19 country-specific interviews with thought-leading medical oncologists Supported by survey data collected for this and other DRG research

Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy

Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2027, segmented by brands/generics and market-relevant drug-treatable populations

 Emerging Therapies: Phase III/PR: 20 drugs; coverage of select Phase I and II products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • March 2019
      • December 2018
      • October 2018
      • September 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Breast Cancer?
        • What Factors Are Constraining the Market for Breast Cancer?
      • Segment-Specific Trends
        • Adjuvant and Neoadjuvant Market
        • First-Line Market
        • Second- and Subsequent-Line Market
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Prognostic Biomarkers
        • Patterns of Metastasis
      • Staging and Classification
        • Staging of Breast Cancer
      • Prognostic Gene Expression Signatures
        • Oncotype Dx
        • MammaPrint
        • The Quest H:I Ratio Test
      • Key Pathways and Drug Targets
        • Key Pathways and Drug Targets for Breast Cancer
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Molecular Subtype
        • Stage at Diagnosis
        • Menopausal Status
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • HER2-Targeted Agents
        • CDK4/6 Inhibitors
        • mTOR Pathway Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
        • SERDs
        • PARP Inhibitors
        • Immune Checkpoint Inhibitors
        • PI3K Inhibitors
      • Medical Practice
        • Neoadjuvant Treatment of Stage II/III Breast Cancer
        • Adjuvant Hormone Treatment of Stage I-III Breast Cancer
        • Adjuvant Chemotherapy Treatment of Stage I-III Breast Cancer
        • Adjuvant Targeted Treatment of Stage I-III Breast Cancer
        • First-Line Hormone Treatment of Advanced/Metastatic Breast Cancer
        • First-Line Chemotherapy Treatment of Advanced/Metastatic Breast Cancer
        • First-Line Targeted Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Hormone Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Chemotherapy Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Targeted Treatment of Advanced/Metastatic Breast Cancer
        • Treatment Guidelines
        • Country-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Breast Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Breast Cancer
        • PARP Inhibitors
        • PI3K/AKT/mTOR Pathway Inhibitors
        • Immune Checkpoint Inhibitors
        • HER2/EGFR-Targeting Agents
        • Cytotoxic Agents
        • HDAC Inhibitors
        • RANKL-Targeting Agents
        • Cancer Vaccines
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Breast Cancer
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Breast Cancer Bibliography
      • Supplemental Breast Cancer Epidemiology Bibliography

Author(s): Paul Wilcock. PhD; Alison Isherwood, MSc, MRes, PhD

Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.

Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.